Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Treating the kidneys — a new era in the United States (and beyond)

Nature Reviews Nephrology volume 15, pages 727–728 (2019)Cite this article

Subjects

Kidney disease is one of the leading causes of death and its prevalence continues to increase worldwide. However, the pace at which new treatments have become available has been excruciatingly slow over the past 30 years. A new White House directive promises to focus the spotlight on accelerating innovations for patients with kidney disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. United States Renal Data System. USRDS Annual Data Report 2018: epidemiology of kidney disease in the United States. USRDS https://www.usrds.org/adr.aspx (2018).

  2. Trump, D. J. Executive Order on Advancing American Kidney Health. The White House https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/ (2019).

  3. Lewis, E. J. et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456–1462 (1993).

    Article  CAS  Google Scholar 

  4. Burton, B. T. Overview of end stage renal disease. J. Dial. 1, 1–23 (1976).

    Article  Google Scholar 

  5. Harris, P. C. et al. The PKD1 gene product. Nat. Med. 1, 493 (1995).

    Article  CAS  Google Scholar 

  6. Lenkkeri, U. et al. Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations. Am. J. Hum. Genet. 64, 51–61 (1999).

    Article  CAS  Google Scholar 

  7. Beck, L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11–21 (2009).

    Article  CAS  Google Scholar 

  8. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).

    Article  CAS  Google Scholar 

  9. Pivert, K. AY 2019 nephrology match—preliminary results. ASN data brief. American Society of Nephrology https://asndataanalytics.github.io/AY-2019-Match/ (2018).

  10. National Institutes of Health. Research Portfolio Online Reporting Tools (RePORT). NIH https://report.nih.gov (2019).

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    William H. Fissell

  2. Schools of Pharmacy and Medicine, Department of Bioengineering & Therapeutic Sciences, UCSF, San Francisco, CA, USA

    Shuvo Roy

Authors
  1. William H. Fissell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuvo Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuvo Roy.

Ethics declarations

Competing interests

W.H.F. and S.R. have ownership in Silicon Kidney, a start-up company that will advance the commercialization of silicon membrane technology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fissell, W.H., Roy, S. Treating the kidneys — a new era in the United States (and beyond). Nat Rev Nephrol 15, 727–728 (2019). https://doi.org/10.1038/s41581-019-0209-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-019-0209-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing